Carregant...
Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors
PURPOSE: In a phase I study, the combination of gemcitabine and imatinib was well tolerated with broad anticancer activity. This phase I trial evaluated the triplet of docetaxel, gemcitabine and imatinib. EXPERIMENTAL DESIGN: Imatinib was administered at 400 mg daily on days 1–5, 8–12 and 15–19. Gem...
Guardat en:
| Publicat a: | Invest New Drugs |
|---|---|
| Autors principals: | , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2010
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5300057/ https://ncbi.nlm.nih.gov/pubmed/20697775 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9504-5 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|